Revolution Medicines Executives Execute Large-Scale Stock Option Exercise and Share Sales: Balancing Short-Term Gains with Long-Term Holdings

Revolution Medicines, Inc. (RVMD) COO Exercises 75,000 Options, Sells 74,000 Shares; Maintains Stake Value of ~$14.32M

Margaret A. Hong, Chief Operating Officer of Revolution Medicines (RVMD), exercised a total of 75,000 stock options on January 7, 2026, and sold 74,000 of those shares in the open market. Two consecutive Form 4 filings dated January 9, 2026, confirmed that she acquired 51,406 shares at a $42.45 strike price and 23,594 shares at $29.80. She then sold 53,096 shares at an average of $100.0164, 20,204 shares at $101.7928 and 1,700 shares at $102.90. All transactions were executed under a pre-established Rule 10b5-1 plan. After the trades, Hong held 141,053 shares (including restricted stock units), representing a stake valued at approximately $14.32 million (≈KRW 20 billion) based on a share price near $101.

## CFO Also Exercises Options and Sells Shares… Management-Wide Profit Realization On the same day, Chief Financial Officer Jack Anders exercised 10,000 options at $42.45 and immediately sold all 10,000 shares at $98.00, as reported in a separate Form 4 filing. The exercise generated a cost of $424,500, while the sale proceeds reached $980,000—implying a pre-tax gain of about $555,500 (≈KRW 780 million). Immediately after the transaction, Anders directly held 108,065 shares (or 118,065 shares per some disclosures), of which 42,338 were restricted stock units, indicating potential future conversion into additional common shares.

Routine, Material Sales Under 10b5-1 Plan… Mixed Market Interpretation

Both Hong’s and Anders’s transactions were made under pre-established Rule 10b5-1 plans, which automate trades based on preset timing and price conditions to reduce concerns over opportunistic insider sales. While Hong realized substantial profits by selling most acquired shares immediately, she still retains a stake exceeding $10 million—prompting investors to debate whether this reflects “strategic portfolio rebalancing” or a signal that management is cashing in at current price levels. The combination of retained holdings and planned trading supports medium- to long-term confidence, but “insider selling” headlines could fuel short-term volatility.

Form 144 Filing Signals Potential Additional Sales… Indicates Expanded Liquidity

A separate Form 144 filing on January 7, 2026, signaled insiders’ intention to sell additional shares of Revolution Medicines. Although the filing did not disclose the planned volume or seller identities, Form 144 requires executives and affiliates to pre-notify sales of restricted or controlled shares. This suggests that further share supply could hit the market in the coming period. While such potential sales may weigh on short-term supply and demand, they could also be viewed as part of lock-up expirations and broader liquidity expansion over the medium term.

## Investor Perspective: Rebalancing Based on Price Levels Weighs More Than Fundamentals These disclosures do not reflect changes in company fundamentals—such as earnings, guidance revisions, financing or M&A—but rather signal management’s portfolio rebalancing at recent price levels. Investors should consider: - Transactions were executed under *Rule 10b5-1* plans. - Both COO Hong and CFO Anders still hold significant stakes. - Form 144 indicates potential future sales, though volumes remain unspecified.

In the short term, insider selling headlines may exert downward pressure on the share price. However, over the medium to long term, clinical progress and business momentum are likely to remain the primary drivers of valuation.

Key Insider Transactions Summary

Category	Executive	Date	Strike / Sale Price (USD)	Shares	Total Amount (USD)	Approx. KRW Equivalent
Option Exercise	COO Margaret A. Hong	2026-01-07	$42.45 / $29.80	75,000	~$2,886,878	~KRW 4.0 B
Stock Sale	COO Margaret A. Hong	2026-01-07	$100.02–102.90	74,000	~$7,400,000	>KRW 10.35 B
Option Exercise	CFO Jack Anders	2026-01-07	$42.45	10,000	$424,500	~KRW 0.59 B
Stock Sale	CFO Jack Anders	2026-01-07	$98.00	10,000	$980,000	~KRW 1.37 B
(1 USD = 1,400 KRW 기준 환산)